Literature DB >> 22179663

Does PTEN loss impair DNA double-strand break repair by homologous recombination?

Clayton R Hunt1, Arun Gupta, Nobuo Horikoshi, Tej K Pandita.   

Abstract

The tumor suppressor PTEN is frequently lost in cancer cells, resulting in altered radiation and drug sensitivity. However, the role of PTEN in DNA repair is controversial. Detailed studies in prostate cancer cells now indicate PTEN does not regulate RAD51 expression or homologous recombination and is not a biomarker for PARP inhibitor sensitivity. ©2011 AACR.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22179663      PMCID： PMC4151559          DOI： 10.1158/1078-0432.CCR-11-3131

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Lack of PTEN sequesters CHK1 and initiates genetic instability.

Authors:  Janusz Puc; Megan Keniry; Hong Shen Li; Tej K Pandita; Atish D Choudhury; Lorenzo Memeo; Mahesh Mansukhani; Vundavalli V V S Murty; Zbigniew Gaciong; Sarah E M Meek; Helen Piwnica-Worms; Hanina Hibshoosh; Ramon Parsons
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

2.  Essential role for nuclear PTEN in maintaining chromosomal integrity.

Authors:  Wen Hong Shen; Adayabalam S Balajee; Jianli Wang; Hong Wu; Charis Eng; Pier Paolo Pandolfi; Yuxin Yin
Journal:  Cell       Date:  2007-01-12       Impact factor: 41.582

3.  Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.

Authors:  Randi G Syljuåsen; Claus Storgaard Sørensen; Lasse Tengbjerg Hansen; Kasper Fugger; Cecilia Lundin; Fredrik Johansson; Thomas Helleday; Maxwell Sehested; Jiri Lukas; Jiri Bartek
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

4.  Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity.

Authors:  G Pappas; L A Zumstein; A Munshi; M Hobbs; R E Meyn
Journal:  Cancer Gene Ther       Date:  2007-04-13       Impact factor: 5.987

5.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

6.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

7.  Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair.

Authors:  Arun Gupta; Qin Yang; Raj K Pandita; Clayton R Hunt; Tao Xiang; Sandeep Misri; Sicong Zeng; Julia Pagan; Jessei Jeffery; Janusz Puc; Rakesh Kumar; Zhihui Feng; Simon N Powell; Audesh Bhat; Tomoko Yaguchi; Renu Wadhwa; Sunil C Kaul; Ramon Parsons; Kum Kum Khanna; Tej K Pandita
Journal:  Cell Cycle       Date:  2009-07-07       Impact factor: 4.534

8.  Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.

Authors:  Mahmoud Toulany; Rainer Kehlbach; Urszula Florczak; Ali Sak; Shaomeng Wang; Jianyong Chen; Markus Lobrich; H Peter Rodemann
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

Review 9.  Chromatin remodeling finds its place in the DNA double-strand break response.

Authors:  Tej K Pandita; Christine Richardson
Journal:  Nucleic Acids Res       Date:  2009-01-12       Impact factor: 16.971

10.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Authors:  Ana M Mendes-Pereira; Sarah A Martin; Rachel Brough; Afshan McCarthy; Jessica R Taylor; Jung-Sik Kim; Todd Waldman; Christopher J Lord; Alan Ashworth
Journal:  EMBO Mol Med       Date:  2009-09       Impact factor: 12.137
View more
  14 in total

Review 1.  Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.

Authors:  Katsutoshi Oda; Michihiro Tanikawa; Kenbun Sone; Mayuyo Mori-Uchino; Yutaka Osuga; Tomoyuki Fujii
Journal:  Int J Clin Oncol       Date:  2017-05-15       Impact factor: 3.402

Review 2.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 3.  Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

Authors:  A Lester; R Rapkins; S Nixdorf; M Khasraw; K McDonald
Journal:  Clin Transl Oncol       Date:  2016-09-21       Impact factor: 3.405

4.  HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.

Authors:  Somaira Nowsheen; Tiffiny Cooper; James A Bonner; Albert F LoBuglio; Eddy S Yang
Journal:  Cancer Res       Date:  2012-09-15       Impact factor: 12.701

5.  Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase.

Authors:  Todd R Mereniuk; Mohamed A M El Gendy; Ana M Mendes-Pereira; Christopher J Lord; Sunita Ghosh; Edan Foley; Alan Ashworth; Michael Weinfeld
Journal:  Mol Cancer Ther       Date:  2013-07-24       Impact factor: 6.261

Review 6.  Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.

Authors:  Ciara C O'Sullivan; Dominic H Moon; Elise C Kohn; Jung-Min Lee
Journal:  Front Oncol       Date:  2014-02-28       Impact factor: 6.244

Review 7.  Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.

Authors:  Stephen Murata; Catherine Zhang; Nathan Finch; Kevin Zhang; Loredana Campo; Eun-Kyoung Breuer
Journal:  Biomed Res Int       Date:  2016-08-24       Impact factor: 3.411

8.  Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.

Authors:  Paul M Wilkerson; Konstantin J Dedes; Eleftherios Pierre Samartzis; Ioannis Dedes; Maryou B Lambros; Rachael Natrajan; Arnaud Gauthier; Salvatore Piscuoglio; Chantal Töpfer; Vesna Vukovic; Frances Daley; Britta Weigelt; Jorge S Reis-Filho
Journal:  Oncotarget       Date:  2017-01-24

9.  Inhibition of PTEN activates bovine non-growing follicles in vitro but increases DNA damage and reduces DNA repair response.

Authors:  Mila Maidarti; Yvonne L Clarkson; Marie McLaughlin; Richard A Anderson; Evelyn E Telfer
Journal:  Hum Reprod       Date:  2019-02-01       Impact factor: 6.918

Review 10.  DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer.

Authors:  Denis Velic; Anthony M Couturier; Maria Tedim Ferreira; Amélie Rodrigue; Guy G Poirier; Fabrice Fleury; Jean-Yves Masson
Journal:  Biomolecules       Date:  2015-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.